Expert Analysis Of Rater Discrepancies Allows Sponsor To Demonstrate Efficacy—Even With A Missing Endpoint
Source: WCG
The Challenge
A small neuroscience pharmaceutical company conducted a 28-day Phase II proof-of-concept clinical trial in 95 patients with a movement disorder.
But there was a problem: The primary study endpoint using remote video assessment failed to meet significance at Day 28. However, using the same scale, investigators who observed the patients in person did find significant improvement in treated patients at Day 28 when compared to placebo. They used the same scale.
The company turned to WCG MedAvante-ProPhase for guidance and expertise, asking to re-analyze the primary endpoint data from all sources.
access the Case Study!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.
Subscribe to Clinical Leader
X
Subscribe to Clinical Leader
This website uses cookies to ensure you get the best experience on our website. Learn more